These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33889627)

  • 1. Eltrombopag-related renal vein thromboembolism in a patient with immune thrombocytopenia: A case report.
    Wu C; Zhou XM; Liu XD
    World J Clin Cases; 2021 Apr; 9(11):2611-2618. PubMed ID: 33889627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Portal vein thrombosis during eltrombopag treatment for immune thrombocytopenic purpura in a patient with liver cirrhosis due to hepatitis C viral infection.
    Kawano N; Hasuike S; Iwakiri H; Nakamura K; Ozono Y; Kusumoto H; Nagata K; Kikuchi I; Yoshida S; Kuriyama T; Yamashita K; Muranaka T; Kawaguchi T; Sata M; Okamura T; Ueda A; Shimoda K
    J Clin Exp Hematop; 2013; 53(2):151-5. PubMed ID: 23995112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Thromboembolism With Eltrombopag: A Case Report of Deep Vein Thrombosis and Bilateral Pulmonary Embolism.
    Ghumman GM; Fatima H; Singh G; Khalid T; Ayoubi M
    Cureus; 2023 Jan; 15(1):e33615. PubMed ID: 36788875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Portal Vein Thrombosis During Eltrombopag Treatment Concomitant Splenectomy for Immune Thrombocytopenia.
    Saito M; Morioka M; Izumiyama K; Mori A; Kondo T
    Cureus; 2021 Aug; 13(8):e17478. PubMed ID: 34589366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
    Maroun MC; Ososki R; Andersen JC; Dhar JP
    Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Massive intrasplenic arterial thrombosis in a patient with chronic ITP during the development of an Evans syndrome.
    Diez-Feijóo R; Rodríguez-Sevilla JJ; Colomo L; Papaleo N; Maiques JM; Gimeno E; Andrade-Campos M; Abella E; Merchan BM; Calvo X; Jimenez C; Román-Bravo OD; Salar A; Sanchez-Gonzalez B
    Thromb Res; 2021 Dec; 208():226-229. PubMed ID: 33714615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
    Weber E; Moulis G; Mahévas M; Guy C; Lioger B; Durieu I; Hunault M; Ramanantsoa M; Royer B; Default A; Pérault-Pochat MC; Moachon L; Bernard N; Bardy G; Jonville-Bera AP; Geniaux H; Godeau B; Cathébras P
    Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
    Kühne T; Imbach P
    Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia.
    Haselboeck J; Kaider A; Pabinger I; Panzer S
    Thromb Haemost; 2013 Apr; 109(4):676-83. PubMed ID: 23389750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute renal failure in a patient with antiphospholipid syndrome and immune thrombocytopenic purpura treated with eltrombopag.
    Sperati CJ; Streiff MB
    Am J Hematol; 2010 Sep; 85(9):724-6. PubMed ID: 20652968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
    Zhang Y; Kolesar JM
    Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
    Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction.
    Gunes H; Kivrak T
    Curr Drug Saf; 2016; 11(2):174-6. PubMed ID: 26560493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag: a novel oral thrombopoietin receptor agonist.
    Corman SL; Mohammad RA
    Ann Pharmacother; 2010 Jun; 44(6):1072-9. PubMed ID: 20460556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
    Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
    Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia.
    Kim YK; Lee SS; Jeong SH; Ahn JS; Yang DH; Lee JJ; Kim HJ
    Blood Res; 2015 Mar; 50(1):19-25. PubMed ID: 25830126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
    Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.